• Celltrion 1Q reported an operating profit of 15.44 billion won, which was a decrease of 92% year-on-year. The estimates initially anticipated 81.19 billion won.
• The net value was 22.44 billion won, dropped by -87% y/y, compared to the estimate which was 46.68 billion won.
• Sales for Celltrion climbed by 23% year-on-year, reaching 736.98 billion won. This however slightly missed the estimates which had predicted 741.25 billion won.
• The analyst consensus for the company was majorly positive, with 19 buys, 1 hold, and 0 sells.
• All these comparisons to past results are based on the values that were reported by the company in their original disclosures.
Celltrion Inc on Smartkarma
Analysts on Smartkarma have been actively covering Celltrion Inc, providing valuable insights into the company’s performance and market position. Tina Banerjee reports that Celltrion (068270 KS) achieved a solid 12% year-over-year growth in its biosimilars business in 2023, driven by new portfolios such as Remsima SC and Yuflyma. The company is optimistic about surpassing a 60% global sales growth target in 2024, aiming for over 40% EBITDA margin. Additionally, Brian Freitas highlights the potential for Celltrion to replace Samsung SDI in the FnGuide Top10 Equal Weight Index at the next rebalance, signaling positive market sentiment towards Celltrion’s position in the index.
Douglas Kim shares insights on the impact of local investors on corporate governance reforms in Korea, noting that Korea is a few years behind Japan in this aspect. Kim also discusses the alpha generation through share buybacks in Korea, indicating Celltrion Inc as one of the top five market cap stocks participating in share repurchases. Moreover, Tina Banerjee highlights Celltrion’s record-high revenue and operating profit in the third quarter of 2023, solidifying its merger stance and demonstrating a strong financial performance.
A look at Celltrion Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
<p>
Celltrion Inc. is seen to have a mixed outlook based on the Smartkarma Smart Scores. While the company scores moderately on factors like Value and Dividend, its Growth, Resilience, and Momentum scores are relatively stronger. With a focus on producing and selling biosimilar products, Celltrion Inc. also offers consignment processing services to other companies. Its main product, Abatacept, is targeted at arthritis treatment. Looking ahead, the company’s potential for growth and resilience, coupled with positive momentum, could position it well for long-term success in the market.
</p>
<p>
Despite some average scores in certain areas, Celltrion Inc. appears to exhibit promising aspects for long-term performance, particularly in growth potential, resilience, and momentum. Investors may want to keep an eye on how the company leverages these strengths to capitalize on market opportunities. With a product portfolio focused on biosimilar products and a significant offering in arthritis treatment through Abatacept, Celltrion Inc. has foundational elements that could contribute to its sustained success in the competitive healthcare industry.
</p>
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
